As an oral administrative multi-target protein-kinase inhibitor, Sorafenib downregulates the activity of RTKs (receptor protein tyrosine kinases include vascular endothelial growth factor receptor 2/3 [VEGFR-2/3], the hepatocyte factor receptor [c-Kit], Fms-like tyrosine kinase [FLT-3], and platelet-derived growth factor receptor-β [PDGFR-β]) and inhibits the proliferation, metastasis, and angiogenesis of HCC cells9–11. This evidence concerns the gene KDR and hepatocellular carcinoma.